VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2021 | Factors impacting response to ICIs in mUC

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, discusses the impact of primary tumor location, histology, and host factors on objective response to immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC). The findings from this retrospective analysis, explained by Dr Gupta, showed no correlation between host and tumor factors, and treatment response or duration of response in patients. This interview took place during the 2021 Genitourinary Cancers Symposium.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter